Childhood T-cell acute lymphoblastic leukemia: The Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium experience

Journal of Clinical Oncology

Volumn 21, Issue 19, 2003, Pages 3616-3622

  Goldberg, John M ^a   Silverman, Lewis B ^a   Levy, Donna E ^a   Dalton, Virginia Kimball ^a   Gelber, Richard D ^a   Lehmann, Leslie ^a   Cohen, Harvey J ^a   Sallan, Stephen E ^a   Asselin, Barbara L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; CORTICOSTEROID; DOXORUBICIN; MERCAPTOPURINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; B CELL LEUKEMIA; CANCER CENTER; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DRUG MEGADOSE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVIEW; T CELL LEUKEMIA; ARTICLE; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; FEMALE; INFANT; MALE; METASTASIS; NEWBORN; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, B-CELL, ACUTE; LEUKEMIA, T-CELL, ACUTE; MALE; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 0142008436     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.10.116     Document Type: Review

References (30)

1. Sen L, Borella L: Clinical importance of lymphoblasts with T markers in childhood acute leukemia. N Engl J Med 292:828-832, 1975
2. Sallan SE: T-cell acute lymphoblastic leukemia in children. Hamatol Bluttransfus 26:121-123, 1981
3. Silverman LB, Gelber R, Sallan SE, et al: Improved outcomes for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01, Blood 97:1211-1218, 2001
4. Clavell LA, Gelber R, Sallan SE, et al: Four agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 315:657-663, 1986
5. Niemeyer C, Gelber R, Sallan SE, et al: Low-dose versus high dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81-01 Update). Blood 78:2514-2519, 1991
6. Schorin M, Blattner S, Sallan SE, et al: Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 12:740-747, 1994
7. LeClerc JM, Billet AL, Sallan SE, et al: Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber ALL Consortium Protocol 87-01. J Clin Oncol 20:237-246, 2002
8. Silverman LB, Gelber R, Sallan SE, et al: Induction failure in acute lymphoblastic leukemia of childhood. Cancer 85:1395-1404, 1999
9. Silverman LB, Declerk L, Sallan SE, et al: Results of the Dana-Farber Cancer Institute Consortium Protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia 14:2247-2256, 2000
10. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
11. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
12. Schrappe M, Reiter A, Riehm H, et al: Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia 14:2205-2222, 2000
13. Maloney KW, Shuster JJ, Camilla BA, et al: Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994. Leukemia 14:2276-2286, 2000
14. Eden OB, Harrison G, Gibson BES, et al: Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukemia, 1980-1997. Leukemia 14:2307-2320, 2000
15. Gaynon PS, Trigg ME, Bleyer WA, et al: Children's Cancer Group trials in acute lymphoblastic leukemia, 1983-1995. Leukemia 14:2142-2148, 2000
16. Reiter A, Schrappe M, Riehm H, et al: Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: A BFM group report. Blood 95:416-421, 2000
17. Amylon MD, Shuster J, Murphy SB, et al: Intensive high dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group study. Leukemia 13:335-342, 1999
18. Asselin BL, Shuster JJ, Amylon M, et al: Improved event-free survival (EFS) with high dose methotrexate (HDM) in T-cell lymphoblastic leukemia and advanced lymphoblastic lymphoma (T-NHL): A Pediatric Oncology Group (POG) Study. Proc Am Soc Clin Oncol 20:367, 2001 (abstr 1464)
19. Pieters R, Kaspers G, Veerman A, et al: Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia. Leukemia 7:392-397, 1993
20. Pieters R, Boer M, Veerman A, et al: Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia: Implications for treatment of infants. Leukemia 12:1344-1348, 1998
21. Schrappe M, Reiter A, Riehm H, et al: Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90. Blood 95:3310-3322, 2000
22. Barredo J, Synold T, Laver J, et al: Difference in constitutive and post-methotrexate folypolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood 84:564-569, 1994
23. Cherlow JM, Steinherz PG, Hammond GD, et al: The role of radiation therapy in the treatment of acute lymphoblastic leukemia with lymphomatous presentation: A report from the Children's Cancer Group. Int J Radiat Oncol Biol Phys 27:1001-1009, 1993
24. Conter V, Schrappe M, Riehm H, et al: Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. J Clin Oncol 15:2786-2791, 1997
25. Laver JH, Barredo JC, Shuster J, et al: Effects of cranial radiation in children with high risk T cell acute lymphoblastic leukemia: A Pediatric Oncology Group report. Leukemia 14:369-373, 2000
26. Pui CH, Mahmoud HH, Evans WE, et al: Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood 92:411-415, 1998
27. Pui CH, Behm FG, Murphy SB, et al: Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med 321:136-142, 1989
28. Dalton VM, Gelber R, Sallan SE, et al: Second malignancies in patients treated for childhood acute lymphoblastic leukemia. J Clin Oncol 16:2848-2853, 1998
29. Cave H, van der Werff ten Bosch J, Manel A, et al: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med 339:591-598, 1998
30. Ferrando AA, Armstrong SA, Neuberg DS, et al: Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: Dominance of HOX dysregulation. Blood 102:262-268, 2003